4
Changes in Ownership
BioXcel Therapeutics, Inc. Filed Acc 0001104659-24-129462
CEO and President sold 3,117 shares at an average $0.36 ($1,131)
- CEO and President acquired 6,110 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Mehta Vimal · CEO and President
Table I: Non-derivative
4 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2024-12-14 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,610 | 58,403 | D | ||
| 2024-12-15 | Exercise or conversion : show line 2 in the form 10b5-1 | +3,500 | 61,903 | D | ||
| 2024-12-16 | Sale : show line 3 in the form 10b5-1 | −983 | $0.36 | $358 | 60,920 | D |
| 2024-12-16 | Sale : show line 4 in the form 10b5-1 | −2,134 | $0.36 | $773 | 59,605 | D |
| Open-market sales · 3,117 sh · avg $0.36 · $1,131 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2024-12-14 | Exercise or conversion : show line 5 in the form 10b5-1 Restricted Stock Units | −2,610 | 13,049 | D |
| 2024-12-15 | Exercise or conversion : show line 6 in the form 10b5-1 Restricted Stock Units | −3,500 | 31,500 | D |
Loading xslF345X05/tm2431371-4_4seq1.xml…